These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 37620691)

  • 1. Different solubilizing ability of cyclodextrin derivatives for cholesterol in Niemann-Pick disease type C treatment.
    Yamada Y; Fukaura-Nishizawa M; Nishiyama A; Ishii A; Kawata T; Shirakawa A; Tanaka M; Kondo Y; Takeo T; Nakagata N; Miwa T; Takeda H; Orita Y; Motoyama K; Higashi T; Arima H; Seki T; Kurauchi Y; Katsuki H; Higaki K; Minami K; Yoshikawa N; Ikeda R; Matsuo M; Irie T; Ishitsuka Y
    Clin Transl Med; 2023 Aug; 13(8):e1350. PubMed ID: 37620691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fine-tuned cholesterol solubilizer, mono-6-O-α-D-maltosyl-γ-cyclodextrin, ameliorates experimental Niemann-Pick disease type C without hearing loss.
    Yamada Y; Miwa T; Nakashima M; Shirakawa A; Ishii A; Namba N; Kondo Y; Takeo T; Nakagata N; Motoyama K; Higashi T; Arima H; Kurauchi Y; Seki T; Katsuki H; Okada Y; Ichikawa A; Higaki K; Hayashi K; Minami K; Yoshikawa N; Ikeda R; Ishikawa Y; Kajii T; Tachii K; Takeda H; Orita Y; Matsuo M; Irie T; Ishitsuka Y
    Biomed Pharmacother; 2022 Nov; 155():113698. PubMed ID: 36116252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential mode of cholesterol inclusion with 2-hydroxypropyl-cyclodextrins increases safety margin in treatment of Niemann-Pick disease type C.
    Yamada Y; Ishitsuka Y; Kondo Y; Nakahara S; Nishiyama A; Takeo T; Nakagata N; Motoyama K; Higashi T; Arima H; Kamei S; Shuto T; Kai H; Hayashino Y; Sugita M; Kikuchi T; Hirata F; Miwa T; Takeda H; Orita Y; Seki T; Ohta T; Kurauchi Y; Katsuki H; Matsuo M; Higaki K; Ohno K; Matsumoto S; Era T; Irie T
    Br J Pharmacol; 2021 Jul; 178(13):2727-2746. PubMed ID: 33782944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Inclusion Solves Insolubility -Translational Research Cycle from Bedside to Bench and Bench to Bedside for Drug Development Targeting Niemann-Pick Disease Type C].
    Irie T
    Yakugaku Zasshi; 2022; 142(4):389-400. PubMed ID: 35370195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and ototoxicity of different cyclodextrins in Niemann-Pick C disease.
    Davidson CD; Fishman YI; Puskás I; Szemán J; Sohajda T; McCauliff LA; Sikora J; Storch J; Vanier MT; Szente L; Walkley SU; Dobrenis K
    Ann Clin Transl Neurol; 2016 May; 3(5):366-80. PubMed ID: 27231706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hydroxypropyl-beta and -gamma cyclodextrins rescue cholesterol accumulation in Niemann-Pick C1 mutant cell via lysosome-associated membrane protein 1.
    Singhal A; Szente L; Hildreth JEK; Song B
    Cell Death Dis; 2018 Oct; 9(10):1019. PubMed ID: 30282967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential Effects of 2-Hydroxypropyl-Cyclodextrins on Lipid Accumulation in
    Hoque S; Kondo Y; Sakata N; Yamada Y; Fukaura M; Higashi T; Motoyama K; Arima H; Higaki K; Hayashi A; Komiya T; Ishitsuka Y; Irie T
    Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32019132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclodextrins: Assessing the Impact of Cavity Size, Occupancy, and Substitutions on Cytotoxicity and Cholesterol Homeostasis.
    Szente L; Singhal A; Domokos A; Song B
    Molecules; 2018 May; 23(5):. PubMed ID: 29783784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polyrotaxane-based systemic delivery of β-cyclodextrins for potentiating therapeutic efficacy in a mouse model of Niemann-Pick type C disease.
    Tamura A; Yui N
    J Control Release; 2018 Jan; 269():148-158. PubMed ID: 29138063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In Vitro and In Vivo Evaluation of 6-O-α-Maltosyl-β-Cyclodextrin as a Potential Therapeutic Agent Against Niemann-Pick Disease Type C.
    Yasmin N; Ishitsuka Y; Fukaura M; Yamada Y; Nakahara S; Ishii A; Kondo Y; Takeo T; Nakagata N; Motoyama K; Higashi T; Okada Y; Nishikawa J; Ichikawa A; Iohara D; Hirayama F; Higaki K; Ohno K; Matsuo M; Irie T
    Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30845767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclodextrin-Based Macromolecular Systems as Cholesterol-Mopping Therapeutic Agents in Niemann-Pick Disease Type C.
    Puglisi A; Yagci Y
    Macromol Rapid Commun; 2019 Jan; 40(1):e1800557. PubMed ID: 30216584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro evaluation of 2-hydroxyalkylated β-cyclodextrins as potential therapeutic agents for Niemann-Pick Type C disease.
    Kondo Y; Tokumaru H; Ishitsuka Y; Matsumoto T; Taguchi M; Motoyama K; Higashi T; Arima H; Matsuo M; Higaki K; Ohno K; Irie T
    Mol Genet Metab; 2016 Jul; 118(3):214-219. PubMed ID: 27184436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclodextrins applied to the treatment of lysosomal storage disorders.
    Ishitsuka Y; Irie T; Matsuo M
    Adv Drug Deliv Rev; 2022 Dec; 191():114617. PubMed ID: 36356931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-Term Treatment of Niemann-Pick Type C1 Disease With Intrathecal 2-Hydroxypropyl-β-Cyclodextrin.
    Berry-Kravis E; Chin J; Hoffmann A; Winston A; Stoner R; LaGorio L; Friedmann K; Hernandez M; Ory DS; Porter FD; O'Keefe JA
    Pediatr Neurol; 2018 Mar; 80():24-34. PubMed ID: 29429782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigating the Mechanism of Cyclodextrins in the Treatment of Niemann-Pick Disease Type C Using Crosslinked 2-Hydroxypropyl-β-cyclodextrin.
    Carradori D; Chen H; Werner B; Shah AS; Leonardi C; Usuelli M; Mezzenga R; Platt F; Leroux JC
    Small; 2020 Nov; 16(46):e2004735. PubMed ID: 33079457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic cyclodextrin treatment of murine Niemann-Pick C disease ameliorates neuronal cholesterol and glycosphingolipid storage and disease progression.
    Davidson CD; Ali NF; Micsenyi MC; Stephney G; Renault S; Dobrenis K; Ory DS; Vanier MT; Walkley SU
    PLoS One; 2009 Sep; 4(9):e6951. PubMed ID: 19750228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lysosomal-specific cholesterol reduction by biocleavable polyrotaxanes for ameliorating Niemann-Pick type C disease.
    Tamura A; Yui N
    Sci Rep; 2014 Mar; 4():4356. PubMed ID: 24619155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. β-Cyclodextrin-threaded biocleavable polyrotaxanes ameliorate impaired autophagic flux in Niemann-Pick type C disease.
    Tamura A; Yui N
    J Biol Chem; 2015 Apr; 290(15):9442-54. PubMed ID: 25713067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intracerebroventricular 2-hydroxypropyl-γ-cyclodextrin alleviates hepatic manifestations without distributing to the liver in a murine model of Niemann-Pick disease type C.
    Yamada Y; Ishitsuka Y; Fukaura-Nishizawa M; Kawata T; Ishii A; Shirakawa A; Sakai T; Tanaka M; Kondo Y; Takeo T; Nakagata N; Motoyama K; Higashi T; Arima H; Seki T; Kurauchi Y; Katsuki H; Higaki K; Ikeda R; Matsuo M; Era T; Irie T
    Life Sci; 2024 Aug; 350():122776. PubMed ID: 38852794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis, characterization, and evaluation of pluronic-based β-cyclodextrin polyrotaxanes for mobilization of accumulated cholesterol from Niemann-Pick type C fibroblasts.
    Collins CJ; McCauliff LA; Hyun SH; Zhang Z; Paul LN; Kulkarni A; Zick K; Wirth M; Storch J; Thompson DH
    Biochemistry; 2013 May; 52(19):3242-53. PubMed ID: 23560535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.